Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Hemostemix Inc (OTC: HMTXF).

Full DD Report for HMTXF

You must become a subscriber to view this report.


Recent News from (OTC: HMTXF)

Hemostemix Announces Two New Strategic Trial Sites in Texas
CALGARY, Alberta, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM) is pleased to announce that it has received all approvals from two significant institutions to be clinical trial sites for the Companyȁ...
Source: GlobeNewswire
Date: August, 16 2018 08:30
Hemostemix Announces First U.S. Patients Treated in Phase II Clinical Trial
CALGARY, Alberta, July 18, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce that it has treated three additional patients including its first two patients in the United States under its continui...
Source: GlobeNewswire
Date: July, 18 2018 08:30
Hemostemix Formalizes World-Class Scientific Advisory Board
CALGARY, Alberta, July 05, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board (“SAB”).   Members of the SAB are all leaders in ...
Source: GlobeNewswire
Date: July, 05 2018 08:29
Hemostemix Announces Major Milestone Achieved With First 3 U.S. Trial Sites for Phase II Clinical Trial Open for Patient Enrollment
CALGARY, Alberta, May 30, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce that it has entered into agreements and has received all approvals from three additional facilities that have agreed to...
Source: GlobeNewswire
Date: May, 30 2018 08:30
Hemostemix Announces New EU Patent Grant
CALGARY, Alberta, May 23, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce that it has been granted a new patent in the European Union (the “EU”) for its patent entitled “Re...
Source: GlobeNewswire
Date: May, 23 2018 08:30
Hemostemix Announces First Patient Treated in Phase II Clinical Trial
CALGARY, Alberta, May 03, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“...
Source: GlobeNewswire
Date: May, 03 2018 08:30
Hemostemix Announces Trial Site for Phase II Clinical Trial
CALGARY, Alberta, April 27, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce that it has entered into an agreement and has received all approvals from the Vancouver Coastal Health Research Insti...
Source: GlobeNewswire
Date: April, 27 2018 08:30
Hemostemix Announces US FDA Clinical Trial Approval
NOT FOR DISSEMINATON TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM), a clinical-stage, autologous cell-therapy company, ...
Source: GlobeNewswire
Date: April, 19 2018 08:30
Hemostemix Signs License Agreement with Aspire Health Science
NOT FOR DISSEMINATION TO U.S. WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc . (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce it has finalized the terms o...
Source: GlobeNewswire
Date: February, 23 2018 08:00
Hemostemix Signs Manufacturing Agreement with Aspire Health Science
CALGARY, Alberta, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE:HEM) is pleased to announce it has finalized the terms of a contract manufacturing services agreement (the “Manufacturing Agreementȁ...
Source: GlobeNewswire
Date: February, 22 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-180.0752670.0752670.0752670.07526710,500
2018-12-17N/A0.094N/AN/A0
2018-12-14N/A0.094N/AN/A0
2018-12-13N/A0.094N/AN/A0
2018-12-12N/A0.094N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-23780780100.0000Short
2018-11-2010,47510,475100.0000Short
2018-11-141,5001,500100.0000Short
2018-11-08174,500250,00069.8000Short
2018-10-02192,500192,500100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HMTXF.


About Hemostemix Inc (OTC: HMTXF)

Logo for Hemostemix Inc (OTC: HMTXF)

Hemostemix is a clinical stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. ACP , our lead clinical stage candidate, is an autologous cell therapy for the treatment critical limb ischemia. ACP is currently in a Phase clinical trail in Canada, South Africa and the United States.

 

Contact Information

 

 

Current Management

  • Dr. Elmar Burchardt / CEO
  • Angus Jenkins / COO
  • David Berman / CFO, IR
  • Dr. Ina Sarel / VP, R amp D
  • Dr. Hardean E. Achneck / Other
  • Angus Jenkins / Chairman
  • Lee Buckler /
  • Robert L. Buckler /
  • Dr. Elmar Burchardt /
  • Victor H. Redekop /

Current Share Structure

  • Market Cap: $4,097,273 - 03/19/2018
  • Issue and Outstanding: 67,858,119 - 09/20/2016
  • Float: 65,802,119 - 10/05/2015

 



Daily Technical Chart for (OTC: HMTXF)

Daily Technical Chart for (OTC: HMTXF)


Stay tuned for daily updates and more on (OTC: HMTXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HMTXF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HMTXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of HMTXF and does not buy, sell, or trade any shares of HMTXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/